306 results
Thumbnail

D1.102 - Md

Thumbnail

D1.105 - Lichen Planus induced by treatment of severe eosinophilic asthma with biological therapy

Thumbnail

D1.106 - Grape polyphenols reduce the concentration of LPS in patients with asthma

Thumbnail

D1.107 - Polyphenol concentrate reduces CRP in asthma patients who have had COVID-19

Thumbnail

D1.108 - Grape polyphenols increase the concentration of BPI in asthma patients who have had SARS-CoV-2

Thumbnail

D1.109 - Predominance of eosinophilic pathogenetic mechanisms in a severe allergic asthma patient on biologic therapy

Thumbnail

D1.110 - Analysis of clinical and anamnestic risk factors of bronchial asthma in children

Thumbnail

D1.111 - Improving severe asthma through psychological management of traumatic life events

Thumbnail

D1.112 - Managing patients with Type 2 inflammation in a joint interdisciplinary “United Airways Clinic” at Lund University Hospital, Sweden

Thumbnail

D1.113 - Severe Asthma and Depression: the Overlooked Burden

Thumbnail

D1.114 - The Hidden Costs of Severe Asthma Treatment: Unveiling the Iatrogenic Burden

Thumbnail

D1.115 - Post-emergency asthma management

Thumbnail

D1.134 - Mapping the Patient’s Journey Prior to Allergen Immunotherapy

Thumbnail

D1.88 - Mepolizumab and intestinal parasitic infection: A case report

Thumbnail

D1.91 - Baseline characteristics and main clinical outcomes of patients receiving tezepelumab in the framework of use in Special Situations prior to commercialization in Spain (T-ROSS Study)

Thumbnail

D1.92 - Results from the EGPAware Delphi study on Red Flags for Suspicion of Eosinophilic Granulomatosis with Polyangiitis (EGPA): current management in Europe

Thumbnail

D1.93 - ICS use trajectories in severe asthma patients on benralizumab: real-life data from 3-years follow-up

Thumbnail

D1.94 - Impact of overweight and obesity on clinical remission and Response to Biologics in Severe Asthma Patients

Thumbnail

D1.95 - Dupilumab-induced eosinophilia: a transient effect

Thumbnail

D1.96 - Impact of Dupilumab-induced Eosinophilia on Pulmonary Function Tests and Patient Reported Outcomes Measures (PROMs)